Explore the words cloud of the NORMOPERF project. It provides you a very rough idea of what is the project "NORMOPERF" about.
The following table provides information about the project.
EBERS MEDICAL TECHNOLOGY SL
|Coordinator Country||Spain [ES]|
|Total cost||2˙570˙850 €|
|EC max contribution||2˙570˙850 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2018-06-01 to 2020-11-30|
Take a look of project's partnership.
|1||EBERS MEDICAL TECHNOLOGY SL||ES (ZARAGOZA)||coordinator||2˙570˙850.00|
EBERS is a leading company in the field of bioreactors and cell culture systems, with a wide international presence in Europe, USA, Australia, and Asia. In the NORMOPERF project we go a step further by targeting the organ transplantation field by bringing to the healthcare market a new portable device for extracorporeal organ preservation based on a patented technology (P201730030). Organ transplantation is in many cases the only effective therapy for end-stage organ failure. However, it is estimated that only 10% of the global organ needs are covered. Traditionally, only organs obtained in optimal conditions have been considered for transplantation. However, organ lack is leading to the increased use of suboptimal grafts (e.g. non-heart beating donors), which poses new challenges. The most important hurdle preventing the clinical use of suboptimal organs is the limitation of static cold preservation (SCP). SCP is well suited for optimal grafts, but not for suboptimal ones since (i) it allows short preservation times (2-20 h), (ii) it does not provide information about the organ viability and (iii) it additionally damages the organ due to ischemia-reperfusion. The solution proposed by EBERS is a new portable medical device based on normothermic perfusion, capable of maintaining human organs in a viable state for sustained periods under physiological conditions. The NORMOPERF project will offer the clinical community a new device for organ preservation that will contribute to increasing the number of organs available for transplantation by making possible the clinical use of a significant part of the suboptimal organs that are currently not even considered for transplantation. Thus, the use of our technology will allow increasing x2-3 the current transplant rates in the short term. According to our conservative estimations, the €2.57 Mill required for this project will mean €21.3M cumulative EBITDA in 5-years, representing a ROI of 723%.
|Webpage||Websites, patent fillings, videos etc.||2019-10-28 17:54:42|
Take a look to the deliverables list in detail: detailed list of NORMOPERF deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NORMOPERF" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NORMOPERF" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Global Alliance for Chronic Diseases SecretariatRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More